MG1 has been investigated in clinical trials as an oncolytic cancer vaccine expressing MAGE-A3, which is a known tumor antigen selectively expressed in several types of tumors, such as NSCLC, melanoma, and certain hematological malignancies [89]. This evidence concerns the gene MUC5B and melanoma.